Kenneth L. van Golen, Ph.D.
12/13/2010
Curriculum Vitae
Personal Data
Name: Kenneth Louis van Golen, Ph.D.
Contact: University of Delaware
Dept. of Biological Sciences
Center for Translational Cancer Research
320 Wolf Hall
Newark, DE 19176
Phone (302) 831-2669
Fax (302) 831-2281
Education
September 1991-April 1996 Ph.D. Cell and Cancer Biology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
September 1982–June 1987 B.S. Double Major, Microbiology and Biochemistry, Michigan State University, East Lansing, Michigan.
Postdoctoral Training
May 1996-June 1999 Postdoctoral Fellow, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Academic Appointments
May 2010-Present Associate Professor of Biological Sciences, University of Delaware, Newark, DE
Sept. 2006-May 2010 Assistant Professor of Biological Sciences, University of Delaware, Newark, DE
July 2001-August 2006 Assistant Professor of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI.
July 1999-August 2006 Adjunct Assistant Professor of Math and Sciences, Madonna University, Livonia, MI.
July 1999- June 2001 Research Investigator, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Academic Administrative Appointments
None
Clinical/Hospital Appointments
None
Consulting Positions
The Councils of Advisors
Other Laboratory Experience
June 1987- August 1991 Research Assistant II, Department of Pharmacology, Division of Molecular Toxicology and Carcinogenesis, Baylor College of Medicine, Houston, TX.
Scientific Activities
Reviewer
Neoplasia
International Journal of Cancer
Breast Cancer Research and Treatment
Breast Cancer Research
Kluwer Academic Publishers (Book chapters on Angiogenesis and Rho GTPases)
Clinical and Experimental Metastasis
Cell Motility and the Cytoskeleton
Carcinogenesis
Cancer Research
Biochemical Journal
Journal of Biological Chemistry
Journal of Cellular Biochemistry
Grants Review
January 2009 Peer reviewer for The Prostate Cancer Charity.
January 2009, 2010 Dept. of Defense Breast Cancer Research Program-IPY-4
December 2006, 2007, 2008 Dept. of Defense Breast Cancer Research Program Concept Award Online Reviewer.
August 2006, 2007, 2008 Dept. of Defense Breast Cancer Research Program-Cell Biology 2
May 2006, 2009 World Cancer Research Fund
July 2003, 2004, 2005 Dept. of Defense Breast Cancer Research Program-Pathobiology 5
January 2004, 2008 Komen Breast Cancer Foundation-Tumor Biology
Fellowships and Grant Support
*Denotes funding obtained at the University of Michigan as an Assistant professor; **Denotes funding obtained since arriving at the University of Delaware
Completed
Sponsor: NIH sponsored University of Michigan Postdoctoral Training Grant
Role: Post-doctoral Fellowship for Kenneth van Golen, Ph.D. (PI: Dr. Robert Todd III)
Title: Identification of Genes Involved in Inflammatory Breast Cancer.
Total Project Period: 05/01/96-05/01/97
Total Direct Costs: $18,000
Sponsor: Susan G. Komen Breast Cancer Foundation
Role: Post-doctoral Fellowship for Kenneth van Golen, Ph.D. (PI: Dr. Sofia D. Merajver)
Title: The Role of 8p Loci and KAI1 Gene in Hereditary and Inflammatory Breast Cancer
Total Project Period: 05/01/97-04/30/00
Total Direct Costs: $105,000
Sponsor: U of M Comprehensive Cancer Center, Munn Idea Award
Role: Co-Investigator (PI: Dr. Sofia D. Merajver) 0% effort
Title: Assessment of Early Determinants in Pancreatic Cancer
Total Project Period: 08/01/99-07/31/00
Total Direct Costs: $7,500
Sponsor: USAMRMC-Idea Award
Role: Co-Investigator (PI: Sofia Merajver) 50% effort
Title: Genetic Determinants of Inflammatory Breast Cancer
Total Project Period: 02/01/00 -03/25/02
Total Direct Costs: $225,000
Sponsor: USAMRMC- Concept Award (68 proposals funded out of 1750; 3.8% funding rate)
Role: Principal Investigator 15% effort
Title: The RhoC Transgenic Mouse as a Realistic Model of Inflammatory Breast Cancer.
Total Project Period: 06/08/00-07/01/02
Total Direct Costs: $74,683
*Sponsor: NIH, SPORE in Prostate Cancer Career Development
Role: Principal Investigator 30% effort
Title: The role of caveolin-1 in the progression of prostate cancer.
Total Project Period: July 2002-August 2003
Total Direct Costs: $69,973
*Sponsor: U of M Comprehensive Cancer Center, Thomas and Suzanne McPhee Pancreatic Research Fund
Role: Principal Investigator 0% effort
Title: The Roles of Ki-Ras and RhoC GTPase in Pancreatic Cancer
Total Project Period: 03/01/02-07/31/03
Total Direct Costs: $20,000
*Sponsor: USAMRMC- Concept Award
Role: Principal Investigator 20%
Title: Understanding the mechanism of farnesyl transferase inhibitor action in the treatment of inflammatory breast cancer
Total Project Period: 08/31/03-12/01/04
Total Direct Costs: $74,683
*Sponsor: U of M Comprehensive Cancer Center, Munn Idea Award
Role: Principal Investigator 0% effort
Title: Development of a transgenic mouse model of breast cancer development.
Total Project Period: 04/01/04-01/30/05
Total Direct Costs: $25,000
*Sponsor: USAMRMC- New Investigator Award
Role: Principal Investigator 50% effort
Title: Differential activation of Rho GTPases during prostate cancer bone metastasis.
Total Project Period: 02/01/04-1/31/06 (No cost extension granted for 1 year 1/31/07)
Total Direct Costs: $225,000
*Sponsor: Burroughs Welcome Fund
Role: Co-Investigator (PI: Sofia Merajver) 10% effort
Title: Genetic Determinants of inflammatory breast cancer.
Total Project Period: 01/01/04-12/31/06
Total Direct Costs: $250,000
*Sponsor: USAMRMC- Idea Award
Role: Co-Investigator (PI: Mark Day) 5% effort
Title: The Role of ADAM15 in prostate cancer progression.
Total Project Period: 02/01/04-1/31/07
Total Direct Costs: $150,000 per year
*Sponsor: Gift Fund for Pancreatic Research in Memory of Howard Flint
Role: Principal Investigator 0% effort
Title: Pancreatic Cancer Research
Total Project Period: Open
Total Direct Costs: $110,215 total
**Sponsor: University of Delaware Research Fund (UDRF)
Role: Principal Investigator 0% effort
Title: Activation of RhoC GTPase by the heterotrimeric Ga12 subunit in pancreatic cancer.
Total Project Period: 06/2007-05/2008
Total Direct Costs: $25,000 total
Active
**Sponsor: USAMRMC- Idea Award
Role: Principal Investigator 10% effort
Title: Mechanism of action of Ac-PSCN-NH3, a novel compound that inhibits prostate cancer recurrence and metastasis.
Total Project Period: 10/2008-11/2010
Total Direct Costs: $150,000 per year
**Sponsor: USAMRMC-Idea Award
Role: Principal Investigator 10% effort
Title: RhoC GTPase and Akt/PKB as novel therapeutic targets for inflammatory breast cancer.
Total Project Period: 09/2008-10/2011
Total Direct Costs: $150,000 per year
**Sponsor: USAMRMC- PCRP Idea Award
Role: Principal Investigator 25% effort
Title: Prevention of skeletal metastasis by targeting the insulin-like growth factor I receptor
Total Project Period: 03/2008-04/2011
Total Direct Costs: $125,000 per year
**Sponsor: USAMRMC- BCRP Idea Award
Role: Principal Investigator 25% effort
Title: Rho GTPases in Breast Cancer Cell Dormancy.
Total Project Period: 05/2008-06/2011
Total Direct Costs: $125,000 per year
**Sponsor: USAMRMC- BCRP Predoctoral Award
Role: Mentor (Madhura Joglekar P.I.)
Title: Rho GTPases in Breast Cancer Cell Dormancy.
Total Project Period: 04/2010-03/2013
Total Direct Costs: $30,000 per year
Honors and Awards
2010 Co-Chair, EGFR Signaling, BIT Peptide Conference, Beijing, China
2009 Inflammatory Breast Cancer World Alliance Board Member
2008 Co-Chair of Scientific Advancements, First International Congress on Inflammatory Breast Cancer
2004 World Conference on Antineoplastics Young Investigator Award
2001 “Celebrate Invention” award for Invention Disclosure of the RhoC antibody.
2000 Nomination and selection to the Central Society for Clinical Research.
2001 American Association for Cancer Research-AFLAC Young Investigator Award.
1999 The University of Michigan Comprehensive Cancer Center Research Symposium First Prize for Outstanding Research.
1999 Dept. of Defense Breast Cancer Research Program Idea Award.
1999 Munn Idea Award for Pancreatic Cancer Research.
1997 The Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship Award.
1996 The University of Michigan Postdoctoral Training Grant.
1995 American Association for Cancer Research Histopathobiology of Neoplasia Workshop Training Grant.
1995 First Award for Basic Science Research, National Student Research Forum.
1994 The John P. McGovern Award for Outstanding Graduate Research.
1991 R.E. “Bob” Smith Graduate Research Fellowship.
Memberships in Professional Societies
December 2008-Present Inflammatory Breast Cancer World Alliance
April 2007-Present Society for Basic Urologic Research
June 2000-present Central Society for Clinical Research
August 1999-2006 Insulin-like Growth Factors (IGF) Research Society
July 1995-present American Association for the Advancement of Science
August 1994-present Metastasis Research Society
January 1992-present American Association for Cancer Research
November 2001-2006 Cancer Center Member, University of Michigan
Teaching Activities
Extramural Invited Presentations: International, Regional and Local
2010
“Inflammatory Breast Cancer Metastasis: The Role of RhoC GTPase.” The University of Iowa, Iowa City, IA, April 2nd.
“Rho and Rac GTPases in Prostate Cancer Invasion and Diapadesis.” Lincoln University, Lincoln University, PA, March 30th.
“EGFR Signaling in Inflammatory Breast Cancer Invasion.” BIT Peptide Conference, Beijing, China, March 21st.
2009
“Breast Cancer Research” American Cancer Society Making Strides Against Breast Cancer Corporate Breakfast. Chase Center, Wilmington, DE, August 20th.
“Inflammatory Breast Cancer: An update on research from the van Golen Laboratory at the University of Delaware”. Symposium on Inflammatory Breast Cancer, St. Augustinus Hospital, The University of Antwerp, Antwerp, BE, June 24th.
“Inflammatory Breast Cancer” Delaware Breast Cancer Coalition Annual Update Meeting. April 29th.
“RhoC GTPase in Pancreatic Cancer” Translational Cancer Meeting, Helen F. Graham Community Cancer Center, Newark, DE April 20th
2008
“Breaking News in Inflammatory Breast Cancer Research” First International Congress on Inflammatory Breast Cancer, M.D. Anderson Cancer Center, Houston, TX, December 5th.
“Rho GTPases and the aggressive prostate cancer phenotype” Thomas Jefferson University Dept. of Urologic Science. Philadelphia, PA, November 26th.
“Rho GTPases and the invasive prostate cancer phenotype.” Translational Cancer Meeting, Helen F. Graham Community Cancer Center, Newark, DE October 20th
“Akt1, not Akt2 is involved in RhoC GTPase-mediated invasion of inflammatory breast cancer cells.” Dept. of Defense Era of Hope Breast Cancer Research Program Meeting. Baltimore, MD, June 25th.
“The roles of Rho and Rac GTPases in Prostate Cancer Cell Extravasation and Invasion” Joint meeting of the Society for Basic Urologic Research and American Urologic Society, Orlando, FL, May 17th.
2007
“Rho GTPases in Prostate Cancer Cell Extravasation” Delaware State University, Dover, DE November 1st.
“All Rhos Lead to Cancer Progression” Annual Meeting of the American Association for Cancer Research Educational Session (Rho GTPases and Cancer), Los Angeles, CA April 13th.
“RhoC GTPase and the Metastatic Phenotype.” Lankenau Institute for Medical Research (LIMR), Winwood, PA March 1st.
2006
“RhoC GTPase in Metastasis” Delaware Biotechnology Institute Luncheon Seminar Series. December 14th.
“Rho GTPases in Prostate Cancer Cell Diapedesis and Invasion.” The Center for Translational Cancer Research, University of Delaware, Newark, DE April 18th.
“Understanding the Roles of RhoC and Rac GTPases in Prostate Cancer Invasion and Bone Metastasis” Han-Mo Koo Memorial Seminar Series, The Van Andel Research Institute, Grand Rapids, MI March 8th.
“Control of Pancreatic Cancer Cell Growth, Migration and Metastasis by RhoC GTPase and Caveolin-1” Cell Signalling World 2006, Luxembourg, January 27th.
“RhoC GTPase in Inflammatory Breast Cancer and Prostate Cancer Bone Metastasis” Sint Augustine Hospital, University of Antwerp, Antwerp Belgium, January 23rd.
2005
“Control of Pancreatic Cancer Cell Growth, Migration and Metastasis by RhoC GTPase and Caveolin-1” University of Michigan Apoptosis Work in Progress Seminar Series. February 2nd.
2004
“Contribution of RhoC GTPase to the aggressive cancer phenotype” Sint Augustine Hospital, University of Antwerp, Antwerp Belgium September 13th.
“Inhibition of the RhoC GTPase-mediated phenotype by farnesyl transferase inhibitiors” World Conference on Antineoplastics, Congress-Center Nurnberg, Nurnberg, Germany September 9th.
“The role of RhoC GTPase in prostate cancer cell motility and invasion” Michigan Prostate Cancer Colloquium and the 4th annual Symposium in Basic and Clinical Advances in Prostate Cancer Research. Van Andel Research Institute, Grand Rapids, MI May 1st.
“RhoC GTPase is required for prostate cancer cell invasion but not motility”. University of Michigan Urology Research Conference February 10th.
“RhoC and prostate cancer” University of Michigan Dept. of Neurology Special Seminar, Ann Arbor MI, February 13th
2003
“Modulation of Aggressive Cancer Phenotypes by RhoC GTPase”. University of Delaware Dept. of Biological Sciences Seminar, Wilmington, DE October 22nd.
“RhoC GTPase effect on the phenotype of breast cancer”. CNIO Symposium, International meeting on the Rho GTPases in Cancer, Madrid Spain, June 15th.
“RhoC GTPase as a Potential Prognostic Marker and Therapeutic Target for Aggressive Cancers”, The Institute for Drug Development, San Antonio, TX, March 27th.
2002
“Control of Pancreatic Cancer Cell Motility by Caveolin-1” Pancreatic Cancer Interest Group Seminar, The University of Michigan, Ann Arbor, MI, October 15th.
“The Role of RhoC GTPase in Aggressive Breast Cancer” Amgen Corporation Research Seminar, Thousand Oaks, CA July 22nd.
2001
“RhoC GTPase, a Transforming Oncogene of Mammary Epithelium, Stimulates Expression of Genes Involved in Cytoskeletal Reorganization and Motility.” Annual Meeting of the American Association for Cancer Research. New Orleans, LA March 24th.
“The Role of RhoC GTPase as a Transforming Oncogene in Mammary Epithelial Cells.” Wayne State University Department of Pathology Seminar Series. Detroit, MI January 24th.
“RhoC GTPase Acts as a Transforming Oncogene in Mammary Epithelial Cells.” Division of Hematology/Oncology Seminar Series. Ann Arbor, MI January 15th.
2000
“RhoC GTPase Induces a Motile and Invasive Phenotype in Inflammatory Breast Cancer.” The VIII International Congress of the Metastasis Research Society. London England, September 25th.
“The Importance of Fundraising to Translational Research.” The Susan G. Komen/BMW Ultimate Drive. Ann Arbor, MI June 21st.
“The Potential Role of RhoC GTPase in Determining the Invasive and Metastatic Phenotype of Inflammatory Breast Cancer.” Karmanos Cancer Institute Research Seminar. Detroit, MI June 6th.
“RhoC GTPase Acts as a Transforming Oncogene for Human Mammary Epithelial Cells that Partially Recapitulates the Inflammatory Breast Cancer Phenotype.” The University of Michigan Department of Internal Medicine Research Symposium, Ann Arbor, MI June 4th.
“The Potential Role of the RhoC GTPase Oncogene in Inflammatory Breast Cancer.” The 91st Annual Meeting of the American Association for Cancer Research. San Francisco, CA, April 5th.
“RhoC GTPase in Determining the Inflammatory Breast Cancer Phenotype.” The University of Michigan Department of Neurology Special Seminar, Ann Arbor, MI, February 18th.
1999
“Progress in the Study of the Determinants of the Inflammatory Phenotype.” The University of Michigan Breast Oncology Program, Ann Arbor, MI, May 11th.
“Identification of Two Genes Involved in Inflammatory Breast Cancer” First Award Lecture for Outstanding Research by a Young Investigator, The University of Michigan Comprehensive Cancer Center Research Symposium, Ann Arbor, MI, December 10th.
1998
“Identification of Genes Differentially Expressed in Inflammatory Breast Cancer.” University of Michigan, Research Seminar, Ann Arbor, MI, May 4th.
“Identification of Genes Which May Lead to the Pathogenesis and Progress of Inflammatory Breast Cancer.” The M.D. Anderson Department of Cancer Biology, The University of Texas Special Seminar on Metastasis Research, Houston, TX, June 4th.